Pharmaceutically acceptable of N- (4-((3- (2-amino-4-pyrimidinyl) -2-pyridinyl) oxy) phenyl) -4- (4-methyl-2-thienyl) -1-phthalazinamine Crystal forms of the salts obtained and their use
The present invention relates to a compound N- (4-((3- (2-amino-4-pyrimidinyl) -2-pyridinyl) oxy) phenyl) -4- (4-methyl-2-thienyl) -1-phthalazineamine. (Crystal forms and co-crystal forms of pharmaceutically acceptable salts of AMG 900 and pharmaceutical compositions comprising said crystal forms and co-crystal forms. The present invention relates to various types of solids including melanoma and leukemia. Further provided is the use of crystalline forms and compositions for treating cancer, including tumors and hematological cancers.本発明は、化合物Ｎ－（４－（（３－（２－アミノ－４－ピリミジニル）－２－ピリジニル）オキシ）フェニル）－４－（４－メチル－２－チエニル）－１－フタラジンアミン（ＡＭＧ９００の薬学的に許容される塩の結晶形態及び共結晶形態、並びに前記結晶形態及び共結晶形態を含むその薬学的組成物に関する。本発明は、黒色腫及び白血病を含む様々な種類の固形腫瘍及び血液癌が含まれる癌を治療するための、結晶形態及び組成物の使用を更に提供する。
